VRTX
What one share of Vertex Pharmaceuticals Inc / Ma holds
Pharmaceutical Preparations
We are a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases, with a focus on specialty markets. We have approved medicines for cystic fibrosis (“CF”), sickle cell disease (“SCD”), transfusion dependent beta thalassemia (“TDT”), and acute pain, and we continue to serially innovate and advance next-generation clinical and research programs in these areas.
Vertex Pharmaceuticals Inc / Ma’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $49.12 |
|---|---|
| Profit | $17.19 |
| Capex (buildings and equipment) | $1.94 |
| Free cash flow | $14.81 |
| Cash and investments | $53.84 |
| Book value | $79.92 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | $6.96 | −$0.46 | $0.23 | $0.73 | — | $4.66 |
| 2017 | $9.83 | $1.04 | $0.39 | $2.94 | — | $8.01 |
| 2018 | $11.76 | $8.09 | $0.37 | $4.53 | — | $17.38 |
| 2019 | $15.97 | $4.51 | $0.29 | $5.73 | — | $23.50 |
| 2020 | $23.56 | $10.29 | $0.99 | $11.37 | — | $33.42 |
| 2021 | $29.14 | $9.01 | $0.90 | $9.27 | — | $39.69 |
| 2022 | $34.47 | $12.82 | $0.79 | $15.15 | — | $54.13 |
| 2023 | $37.89 | $13.89 | $0.77 | $12.81 | — | $68.22 |
| 2024 | $42.73 | −$2.08 | $1.15 | −$3.06 | — | $63.87 |
| 2025 | $46.52 | $15.32 | $1.70 | $12.38 | — | $73.49 |